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Current progress in nanomedicine has exploited the possibility of designing tumor-targeted nanocarriers being able to deliver
radionuclide payloads in a site or molecular selective manner to improve the eﬃcacy and safety of cancer imaging and therapy.
Radionuclidesofaugerelectron-,α-,β-,andγ-radiationemittershavebeensurface-bioconjugatedorafter-loadedinnanoparticles
to improve the eﬃcacy and reduce the toxicity of cancer imaging and therapy in preclinical and clinical studies. This article
providesa brief overview of current statusofapplications, advantages, problems, up-to-date research and development, and future
prospects of nanotargeted radionuclides in cancer nuclear imaging and radiotherapy. Passive and active nanotargeting delivery of
radionuclides with illustrating examples for tumor imaging and therapy are reviewed and summarized. Research on combing
diﬀerent modes of selective delivery of radionuclides through nanocarriers targeted delivery for tumor imaging and therapy oﬀers
the new possibility of large increases in cancer diagnostic eﬃcacy and therapeutic index. However, further eﬀorts and challenges in
preclinicalandclinicaleﬃcacyandtoxicitystudiesarerequiredtotranslatethoseadvancedtechnologiestotheclinicalapplications
for cancer patients.
1.Introduction
Canceranup-regulatedbiologicalprocessofcellgrowthwith
an ability of tumor cells to invade and metastasize. A century
ago, Paul Ehrlich hypothesized that a “magic bullet” could be
developed to selectively target cancer [1]. Over the past few
decades, the progress in molecular biology and the under-
standing of malignant transformation and tumorigenesis
have revealed two major classes of antitumor therapeutics:
(i) application of molecularly targeted therapeutics to block
major hallmarks of cancer cells, and (ii) employing drug
delivery systems through tumor-targeted nanomedicines to
improve the pharmacokinetics and bioavailability of vehicle-
carried drugs. Targeted cancer therapies can be deﬁned as
drugs developed against a speciﬁc tumor target according to
its important biology function in cancer. From 1980 to 2005,
a total of 205 monoclonal antibodies (mAb) were studied in
clinical trials [2–5]. The US Food and Drug Administration
(FDA) approved the ﬁrst anti-CD20 mAb (Rituximab) for
the treatment of non-Hodgkin’s lymphoma in 1997. Today,
twelve of these anticancer molecular-targeted mAbs have
been approved worldwide, eight of them were approved by
US FDA [3–5].
Conventional anticancer drugs exhibit a lack of speci-
ﬁcity, poor solubility and distribution, unfavorable pharma-
cokinetics, and high-tissue damage or toxicity. Nanotechnol-
ogy can bring fundamental changes to the study and under-
standing of biological processes in health and disease, as
well as enable novel diagnostics and therapeutics for treating
cancer. Thus, advances made on the basis of nanotechnology
could result in progress of healthcare. Targeted drug delivery
systems such as passive and active targeting nanoparticles or
nanocarriers, with diameters ranging from 10–100nm, have
been developed to improve the biodistribution, pharmaco-
logical, therapeutic and toxicity properties of agents used
in cancer diagnostics and therapeutics [6–12]. The status
of the development of targeting delivery systems, including
targeting strategies, potential applications, and the prospects2 Journal of Biomedicine and Biotechnology
of tumor-targeted nanocarriers have been reviewed and
discussed [6–11]. Nanotechnology is attracting increasing
attention in the biomedical community, owing to unique
prospects for targeted delivery in imaging, therapy, and drug
delivery. Cancer nanotechnology is expected to transform
currenttreatmentsystemsbyproviding moreeﬃcient cancer
diagnostics and therapeutics. Today, nanocarriers are used
in detecting cancer at an early stage, delivering anticancer
drugs speciﬁcally to malignant cells, and determining if these
drugs are killing malignant cells [9–13]. Two therapeutic
nanocarrier-liposomes and albumin nanoparticles have been
approved by US FDA for clinical practices [8, 12, 13].
Pegylated liposomal doxorubicin represents a new class of
chemotherapydeliverysystemthatmaysigniﬁcantlyimprove
the therapeutic index of doxorubicin through improving
therapeutic pharmacokinetics [6]. As nanocarriers are evalu-
ated for safety and eﬃcacy, nanotechnology will bring with
it signiﬁcant advances in molecular imaging and speciﬁc
targeting of tumor therapeutic agents, elevating therapeutic
eﬃcacy, and ﬁnally achieving the goal of early detection
and control of cancer. Customized nanoscale constructs
can serve as targeted drug delivery vehicles capable of
delivering large doses of radionuclide or chemotherapeutic
agents into malignant cells while sparing normal tissues,
greatly reducing the side-eﬀects that usually accompany
many current cancer therapies [8–13].
Monoclonal antibody-guided radiation therapy, or
radioimmunotherapy, demonstrated promise in preclinical
and clinical anticancer applications [14–19]. The principles
and applications of molecular targeting involving radionu-
clide methods for tumor nuclear imaging and therapy were
reviewed and discussed [19]. Two radiolabeled anti-CD20
monoclonal antibodies 90Y-ibritumomab (Zevalin) and 131I-
tositumomab (Bexxar) were approved by US FDA in 2002
and2003,respectively,fortreatmentofB-cellnon-Hodgkin’s
lymphoma (NHL), which indicates the potential beneﬁt
of antibody-guided systemic radionuclide-targeted therapy
[16–18]. However, tumor targeting studies with radiolabeled
mAbs also showed some limitations, such as, ineﬃcient
targeting and low accumulation in tumor sites (<0.1 % of
injection dose per gram (%ID/g) of tumor for human) and
irradiation of normal tissues for long circulation of mAbs.
Emerging new methods for improving the speciﬁc uptake
of radionuclides in tumor cells while sparing the normal
tissues need to be established. Several advanced strategies
for radionuclide-targeted delivery have been studied exten-
sively, including the combination of chemotherapy agents
with particle-emitting radionuclides and the development
of novel multimodality and multifunctional nanotargeted
therapeutics [20, 21]. Optimization of treatment protocols
has signiﬁcantly improved the therapeutic eﬃcacy and
reduced toxicity in normal tissues. Nanoparticles delivering
radionuclides for improving pharmacokinetics and thera-
peutic eﬃcacy of cancer have been presented elsewhere [20–
22]. The goal of this article is to review and summarize the
recent research progress and future prospects of advanced
nanoparticles or nanocarriers to deliver radionuclides for
cancer in vivo nuclear imaging and therapeutic applica-
tions.
2. Nanoparticles and Radionuclides for Tumor
Nuclear Imaging and InternalRadiotherapy
2.1. Nanoparticles for Tumor Nuclear Imaging and Radio-
therapy. Major challenges of drug delivery carriers in cancer
diagnostics and therapeutics are the low drug bioavailability
within cancer cells and the high toxicities to normal organs
[22, 23]. Targeted radionuclide therapy is often limited
by insuﬃcient delivery of radionuclides to tumor sites
using the currently available targeting strategies, such as
monoclonal antibodies and peptides, due to relatively low
and heterogeneous expression of receptors on tumor cells,
as well as dose-limiting toxicities to normal tissues. To
maximize the therapeutic index and to minimize the toxicity,
it is very important to deliver the radionuclides to the
right site at the right concentration and at the right time.
The rapidly advancing ﬁeld of cancer nanotechnology has
generated several innovative radionuclides and drug delivery
systems, such as liposomes [23–31], iron oxide [32–34],
polymers [35], dendrimers [36], quantum dots [37–39], and
carbon nanotubes [40], to improve and enhance targeted
transport of cytotoxic drugs or radionuclides to tumor
lesions [20–23, 41, 42]. It is estimated that approximately
240 nano-enabled products entered pharmaceutical research
pipelines in 2006 [43]. These nanocarrier systems could
provide the delivery platforms needed for improving the
delivery of radionuclides to tumor sites. Nanoparticles or
nanocarrier delivery systems have also revealed enhanced
imagingandtherapeuticeﬃcacybytargeteddeliveryofdrugs
to the tumor site and by reducing their toxic side-eﬀects
[7–13]. Major advantages of nanocarriers are that they can
be prepared in sizes <100nm, and increase selectively the
localizationof drugsandradionuclides in thetumorthrough
theirnanosizeorenhancedpermeabilityandretention(EPR)
eﬀect of passive targeting to the leaky tumor tissues [20,
21], or nanoparticle surface bio-conjugation, while sparing
nontargeted tissue, ensuring minimal drug or radionuclide
leakage during circulation, and facilitating intracellular drug
or radionuclide delivery and uptake by active targeting [22,
23, 41, 42, 44]. Two major mechanisms for radionuclide- or
drug-targeted accumulation delivery system of nanoparticles
to tumor tissue sites are (i) site-speciﬁc passive tumor
targeting and (ii) molecular aﬃnity and site-speciﬁc active
tumor targeting for tumor diagnostics and therapy as shown
in Figure 1(a) [7].
There are three generations of nanocarriers or nanopar-
ticles developed: (i) the ﬁrst generation of nanocarriers
(passive targeting) which are rapidly trapped in the reticu-
loendothelial system (RES) organs (e.g., liver and/or spleen)
[25–27, 29, 31], (ii) the second generation of sterically
stabilized PEGylated nanocarriers (passive targeting), which
can evade the RES of the liver and spleen, enjoys a
prolonged circulation in the blood and allows for passive
targeting through the enhanced permeability and retention
(EPR) eﬀect in leaky tumor tissues [25–27, 29, 31], and
(iii) the third generation of nanocarriers with a biocon-
jugated surface modiﬁcation of the nanoparticles using
speciﬁc antibodies or peptides to actively target speciﬁc
tumor or tissues through molecular interaction or aﬃnityJournal of Biomedicine and Biotechnology 3
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Figure 1: (a) Schematic illustration showing the possible mechanism for radionuclides or drug accumulation delivery system of
nanoparticles by site speciﬁc passive tumor targeting using the enhanced permeability and retention (EPR) eﬀect or molecular aﬃnity
and site speciﬁc active tumor targeting through ligand tumor cell surface receptors interaction, internalization, and intracellular action for
tumordiagnosticsandtherapy(reproducedwithmodiﬁcationwithpermissionfrom[7]).(b)Schematicdiagramoftumortissuepenetration
range of internal radiotherapy by auger electron (0.1–2keV, <1μm )-, α (5–8MeV, 50–80μm range)-, and β (0.1–2.2MeV, 1–10mm range )-
radiation emitters for passively and actively nanotargeted radionuclide therapy (reproduced with modiﬁcation with permission from [14]).4 Journal of Biomedicine and Biotechnology
(active targeting) [22, 32–42, 44–52]. The pharmacokinetics
and bioavailability of drugs and radionuclides delivered
by the third-generation nanocarriers have been much
improved. There are three major challenges of applying
nanoparticles to delivery of drugs or radionuclides: (i)
synthesizing nanocarriers with stealth characteristics which
are able to decrease uptake of delivered diagnostic and ther-
apeutic agents in the reticuloendothelial system (RES) and
prolong blood circulation, (ii) producing multifunctional
nanoparticles with improved in vivo targeting capabilities,
and interaction with disease biomarkers at the molecular
level, (iii) developing reliable approaches to test these new
materials in vitro and in vivo for a fast translation from the
bench to the bedside [21, 42].
There are ﬁve approaches generally used for labeling
or encapsulating radionuclides on nanoparticles: (i) label-
ing nanocarriers by encapsulation during preparation, (ii)
nanocarrierssurfacelabelingafterpreparation,(iii)nanocar-
rier surface labeling of bioconjugates after preparation, (iv)
incorporation into the lipid bilayer after preparation, and (v)
after-loading of the aqueous phase of the nanocarriers after
preparation. The after-loading method has provided higher
labeling eﬃciencies (>90%) and the greatest in vivo stability
for 99mTc, 111In, and 67Ga radionuclides for nuclear imaging
[20, 21, 24, 30, 31, 42, 53].
2.2. Radionuclides for Tumor Nuclear Imaging and Radio-
therapeutics. The research on tumor-targeted diagnostic and
therapeutic radionuclides is one of the potential areas of
cancer drug development. Normally, targeted radionuclides
consist of two components, a targeting carrier and a trace
amount of radionuclide with a speciﬁc radiation emitter.
The tumor therapeutic eﬃcacy and diagnostic quality are
determined by the selectivity or speciﬁcity of the targeted
delivery systems and the radionuclide radiation character-
istics [14, 15, 20, 21]. The selection of potential targeted
radionuclides for tumor imaging (Table 1)a n dt a r g e t e d
radionuclide for internal radiotherapy (Table 2) involves the
physical half-life, decay mode, and the emission properties
of the radionuclides. Gamma emitters with energy range
between 130 and 370keV can be used for gamma imaging
or single photon emission tomography (SPECT) [24–30].
The high-energy positron emitters with annihilation energy
at 511keV energy can be applied for positron-emission
tomography (PET) [20, 21, 31]. The major characteristics
of nanotargeted nuclear imaging modalities are listed in
Table 3. In functional and molecular imaging, the in vivo
radionuclide SPECT and PET imaging is the most sensitive
with sub-nanomolar amounts of molecular probes and the
highest tissue penetration range (Table 3).
For targeted radionuclide internal radiotherapy appli-
cations, high- and low-energy between 0.1–2.2MeV of β-
emitters are ideal radioisotopes for the treatment of small
to large clusters of tumor cells [14]. The maximum tissue
penetration range (1–10mm) [14, 54] and cross-ﬁre eﬀects
of β-particles with energy range between 0.1–2.2MeV can
kill tumor cells in close proximity to neovasculature [14,
21, 54]. Alpha-emitters hold great promise as therapeutics
for small cancer lesions and micrometastatic cancers due to
the high-linear energy transfer (LET, 80keV/μm) and short-
range energy depositions with tissue penetration range of
50–100μm. Monoclonal antibody labeled with α-emitters
has been demonstrated to have high speciﬁc killing eﬀects
and minimal normal-tissue damage in a tumor-bearing
animal model [14, 54]. Auger electrons have an energy of
<30keV and subcellular pathlength of 2–12μm. Thus, auger
electron emitters can exert their radiotoxic eﬀects on cells
when they are internalized into the cytoplasm [55–57].
123I-ITdu-mediated nanoirradiation of DNA induces
eﬃciently death in HL60 leukemia cells and in doxorubicin,
β-o rγ-radiation-resistant cell lines has been examined. The
experimental ﬁndings provide evidence that ultra-selective
nanoirradiation of DNA through auger electron-carrying
metabolic substrates oﬀers an extremely eﬀective strategy
for inducing cell death and breaking resistance to more
conventional types of irradiation or chemotherapy [58]. The
schematic illustration of tumor tissue penetration range of
radiation emitters for passively and actively nanotargeted
radionuclide therapy is shown in Figure 1(b) [14].
3.PassiveNanotargetingDeliveryof
Radionuclides for Tumor Nuclear Imaging
and Radiotherapy
Typically,nanotargetedradionuclideshaveatwo-component
architecture for passive targeting imaging and radiothera-
peutics for example, a pegylated nanoliposome loaded with
radionuclide payloads for nuclear imaging or radiothera-
peutics [20, 21, 31, 59]. The research and applications of
selected passively nanotargeted nuclear imaging agents and
radiotherapeutics are summarized in Table 4. The history
and progress of the preclinical development of liposome-
targeted treatments for cancer before 2000 were described
in detail [60]. Optimal radiolabeled liposomes for tumor
imaging have been established [61]. The clinical develop-
ment of passively targeted liposomes as vehicles for targeted
therapy of cancer have been summarized [62]. In addition,
the potential areas for future development of liposome-
targeted strategies have also been considered [62].
Drug and radionuclides encapsulated within the lipo-
some can occur in one of the three potential compartments:
water-soluble agents are located in the central aqueous core
of the liposome; lipid-soluble agents are carried in the
liposome membrane; peptides and small proteins tend to
bind to the interface between the lipid bilayer surface and the
adjacent aqueous phase [60].
3.1.PassiveNanotargetingDeliveryofRadionuclidesforTumor
Nuclear Imaging. The major characteristics of nanotargeted
nuclear imaging modalities such as gamma imaging, SPECT
and PET are listed in Table 3. Liposomes are self-assembling
colloidal particles composed of a spherical bilayer of small
phospholipid vesicles which is spontaneously formed when
water is added to a dried lipid mixture [60]. Signiﬁcant
progress has been made in the use of liposome as a
nanoparticle or nanocarrier for the delivery of radionuclidesJournal of Biomedicine and Biotechnology 5
Table 1: Characteristics of potential radionuclides for nanotargeted tumor imaging [20, 21, 28, 29].
Radionuclide Production Emission type Half-life Emax(γ), (keV)
131I 130I(n, γ)131Te (β) 131I γ (81.2%), β 8.0 days 284, 364, 637
67Ga 68Zn (n, p)67Ga γ 78.3h 93, 184, 300, 393
111In 111Cd (p, n)111In Auger, γ 67.2h 171, 245
123I 121Sn (α,2 n ) 123I Auger, γ 13.2h 159
99mTc 99Mo/99mTc-generator γ 6.0h 140
18F 18O( p ,n ) 18F Positron 1.83h Eβ+ 635
64Cu 64Ni(p, n)64Cu Positron 12.7h Eβ+ 656
76Br 76Se(p, n)76Br Positron 16.0h Eβ+ 3941
124I 124Te(p, n)124I Positron 100.2h Eβ+ 2134, 1533
Table 2: Characteristics of potential radionuclides for tumor radiotherapy [14, 15, 19–21, 54, 55].
Radionuclide Production Emission type Half-life Emax (MeV) Rmax (mean)1 Size of tumor cells2
186Re 185Re (n, γ)186Re β, γ (9.4%) 89.2h 1.07 5mm (1.8mm) Intermediate clusters
188Re 188W/188Re-generator β, γ (15.1%) 17h 2.12 11mm (2.4mm) L clusters
177Lu 176Lu (n, γ)177Lu β 161h 0.49 1.6mm (0.67mm) S clusters
131I 131Te (β)131I γ (81.2%), β 8d 0.28, 0.36, 0.64 2.4mm (0.8mm) S clusters
90Y 90Sr/90Y-generator β 64.1h 2.28 12mm (2.8mm) L clusters
67Cu 64Ni(α,p ) 67Cu β 2.6d 0.19 2.2mm (0.7mm) S clusters
225Ac 225Ra-generaor α 10d 5.83, 5.79, 5.79, 5.73 40–80μm Single cells, S clusters
111In 111Cd (p, n)111In Auger,γ 67h 0.42 2–500nm Single cells
L: large; S: small.
1Radiation tumor tissue penetration maximum and mean range.
2Small, intermediate and large clusters correspond approximately to the intervals 104–106,106–108,a n d1 0 8–1010 tumor cells per clusters, respectively [54].
for imaging. Selected research and applications of passively
nanotargeted cancer nuclear imaging agents and radiothera-
peutics are summarized in Table 4.
Delivery of 99mTc, 111In, and 67Ga radionuclides by lipo-
somes for gamma-imaging and monitoring drug treatment
have been reviewed and reported for preclinical and clinical
studies[28,29,60–63].Asystemicstudyofoptimalliposome
formulation and encapsulation of radionuclides was also
reported [60, 61]. The biodistribution, pharmacokinetics,
and nuclear imaging of 111In-DTPA-labeled pegylated lipo-
some were studied in patients with advanced local cancer
[53]. Eﬀective targeting of solid tumors of breast (5.3 ± 2.6
%ID/kgforatumorvolumeof234.7 ± 101.4cm3),headand
neck (highest uptake of 33.0 ± 15.8 %ID/kg for a tumor
volume of 36.2 ± 18.0cm3), lung (18.3 ± 5.7 %ID/kg for
a tumor volume of 114.5 ± 42.0cm3), brain, and cervix
was also observed with gamma camera and SPECT imaging
[53].Conventional 111In-basedliposome(Vescan)preclinical
and clinical performance and evaluation of lessons learned
from the formulation and process development has been
discussed and summarized [64]. In recent years, clinical
studies using radiolabeled liposomes for tumor diagnostic
imaging of cancer and inﬂammation from 1979 to 2001 have
been reported [65]. A novel amphiphilic probes for 18F-
radiolabeling performed liposomes and determination of
liposomal traﬃcking by PET was developed [66]. Liposomes
encapsulating positron emitter 18Fa n d64Cu were applicable
for diagnostic imaging and real-time liposomal tracking in
vivo [66–69].
Wang et al. demonstrated an intravenous administration
of 111In-liposome by conjugating 111In-oxine to DTPA/PEG-
liposome followed by whole-body scintigraphy. Images
revealed that the tumor clearly accumulated 111In-liposome
up to 48h postinjection (p.i.) [70]. In addition to the
diagnostic imaging of 111In-liposome, Lee et al. demon-
strated the bifunctional imaging and bimodality therapeutic
eﬃcacyofradiochemo-therapeuticsof 111In-VNB-liposomes
in HT-29/luc mouse xenografts [71]. Table 4 lists some of
the selected passively nanotargeted liposomes delivery of
radionuclides for nuclear imaging. The gamma scintigraphy
and SPECT/CT image passively nanotargeted radionuclides
of 111In-liposome (Figure 2(a))[ 70], 188Re-liposome, and
188Re-DXR-liposome (Figure 2(c))[ 70, 72] targeting on CT-
26 tumor bearing in BALB/c mice animal model through the
EPR localization eﬀect were illustrated.
3.2.PassiveNanotargetingDeliveryofRadionuclidesforTumor
Radiotherapy. An analytical dosimetry study for the use of
131I, 90Y, 188Re, and 67Cu radionuclide-labeled liposome for
internal radiotherapy has been reported, and the analysis
suggested that the optimal liposome system for radiother-
apy diﬀers from chemotherapy delivery [74]. In previous
clinical targeting tumor imaging studies [53], the results
of the eﬀective targeting of solid tumors in patients with
advanced local cancers by radiolabeled pegylated liposomes
support the possible delivery of β-emitting radionuclide-
loaded pegylated liposome for the treatment of solid tumors,
particularly those liposomes in head and neck patients.6 Journal of Biomedicine and Biotechnology
Table 3: Characteristics of nanotargeted nuclear imaging modalities [20, 21].
Modality Image probe (Amount of probe) Type of radiation Sensitivity Spatial Resolution Depth Nanoparticle design
SPECT 99mTc, 111In etc γ-ray 10−10-10−11 (pM) 0.5–1mm No limit Surface
Bio-conjugation
or after loading
loaded or labeled
nanocarriers (ng)
PET 18F, 64Cu etc Positron 10−11-10−12 (pM) 1-2mm No limit Surface
Bio-conjugation
or after loading
loaded or labeled High energy
nanocarriers (ng) γ-ray
SPECT: single photon emission computed tomography; PET: positron emission tomography.
Bao et al. have developed a method of labeling liposomes
with radionuclides using N,N-bis(2-Mercaptoethyl)-N
 N
 -
diethylethylenediamine (BMEDA) to after-load 99mTc or
186Re into liposomes [65, 75, 76]. In addition to therapy
via intravenous administration, the intratumoral and
intraoperational therapies were also investigated for the
potential use of 186Re-liposomes [77–79]. High-resolution
SPECT/CT images revealed the intratumoral distribution
of therapeutic liposomes; this result indicated the potential
use of 186Re-liposomes for intratumoral therapy [78, 79].
Intraoperative passive nanotargeted 186Re-liposome therapy
showed an excellent tumor suppression and minimal
side-eﬀect proﬁle in the head and neck squamous cell
carcinoma xenograft positive surgical margin model [78].
Biodistribution, pharmacokinetics, and nuclear imaging of
passively nanotargeted radio-therapeutics of 111In/188Re-
liposome on C26 and HT-29 colon carcinoma-bearing
animal models have been studied by our group [70, 72, 80].
111In has a γ-ray with 171keV energy for nuclear imaging
and an auger electron with 0.42MeV energy in the nm tissue
penetration range with speciﬁc single tumor cell or small
tumor cluster killing eﬀect (Table 2 and Figure 1(b)). 188Re
has a γ-ray with 155keV energy for nuclear imaging and a
high-energy beta emitter with 2.12MeV energy for killing
nonspeciﬁc large tumor clusters. Both radionuclides can be
used in bifunctional nuclear imaging and internal radio-
therapeutic applications. The long-circulating pegylated
liposomes radiolabeled with 188Re (188Re-liposomes) showed
a higher uptake in the tumor as compared with 188Re-
BMEDA alone. Passively nanotargeted 188Re-liposomes were
found to have a 7.1-fold higher tumor-to-muscle ratio as
compared with intravenously administered unencapsulated
188Re-BMEDAinaC26murinecoloncarcinomasolidtumor
animal model [72]. Improvement of biodistribution and
therapeutic index via increase of polyethylene glycol(PEG)
from 0.9% to 6% on passively nanotargeted 111In-liposome
in an HT-29/luc xenografted mouse model was observed
[81]. Targeted α-particle emitters are promising therapeutics
for micrometastatic tumors. Enhanced loading of 225Ac and
retention of three α-particle-emitting daughters of 225Ac
by passively targeted liposomes have been demonstrated
[82–84].
Boron neutron capture therapy (BNCT) is a binary
approach to cancer therapy involving the nuclear reaction
that occurs when 10B is irradiated with thermal neutrons to
yield high LET of α-particles and lithium nuclei (2.4MeV).
These particles have a short range (<10μm) and deposit
their energy within single cells. The eﬃcacy and successful
treatment of tumors by BNCT depend on the selective
delivery of relatively high amounts of 10B to tumors. There
are three important parameters for development of boron
compounds: (i) achieving tumor concentration in the range
of 20–35μg 10B/g, (ii) reaching a tumor/normal tissue ratio
greaterthan3–5,and(iii)illustratingsuﬃcientlylowtoxicity.
Application of passive stealth liposome-entrapped 10Bd e l i v -
erysystemshasbeenstudiedforBNCTinanimalmodels[85,
86]. The results of the study on 10B-PEG-liposome through
intravenous injection suggested that passively targeted deliv-
ery of sodium mercaptoundecahydrododecaborate (10BSH)
can increase the retention of 10B by tumor cells, causing the
suppression of tumor growth in vivo for BNCT [86]. A high
level of 10B concentration (22ppm) was observed in tumor
tissues at 24h after the administration of boron liposomes,
and the tumor was signiﬁcantly suppressed [85].
3.3. Passive Nanotargeting Codelivery of Radionuclides and
Chemotherapeutics for Tumor Radiochemotherapeutics. Con-
comitant chemotherapy and radiotherapy has been found
to improve treatment outcome in a range of solid tumors.
Pegylated liposome-encapsulated doxorubicin and cisplatin
have shown to be the potential target drugs to tumors,
showing increase in therapeutic eﬃcacy and reduction
in toxicity [87]. Trimodal cancer therapy combining
antiangiogenesis, chemotherapy, and radiotherapy achieves
beneﬁcial eﬀects when used as a clinical antitumor strategy
[88].Image-guidedandpassivenanocarrier-basedpolymeric
nanomedicine for radiotherapy holds signiﬁcant potential
for improving the treatment of advanced solid tumors [89].
Biodistribution, pharmacokinetics, nuclear imaging, and
therapeutic eﬃcacies were investigated for nanotargeted
bifunctional co-delivery radiochemotherapeutics of 111In/
188Re-(vinorelbine/doxorubicin, VNB/DXR)-liposomes on
colorectal carcinoma of HT-29 and C26 tumor and ascites-
bearing animal models [71, 73, 90–93]. In addition to theJournal of Biomedicine and Biotechnology 7
diagnostic imaging of 111In/188Re-liposome, the additive
therapeutic eﬃcacy was observed for the comparative
co-delivery radiochemo-therapeutics of speciﬁc-killing
auger electron emitters of 111In-(VNB)-liposomes on HT-
29/luc mouse xenografts [71, 92]. 188Re-DXR-liposomes
could provide a beneﬁcial and promising strategy for
the co-delivery of passively nanotargeted bimodality
radiochemotherapeutics in the treatment of solid tumor
and ascites [73, 91]. The experimental results pointed to
the potential beneﬁt of the co-delivery of nanoliposome
radiochemotherapeutics for adjuvant cancer treatment in
oncology applications [73]. Evaluation of pharmacokinetics
of 111In-VNB-liposome on C26/tk-luc after intraperitoneal
(i.p.)andintravenous(i.v.)administrationinatumor/ascites
mouse model was studied and compared, the results
indicatedthatthei.p.wasabetterapproachthani.v.injection
in the treatment of i.p. malignant tumor/ascites model [93].
Previous theoretical dosimetry studies have addressed the
potential use of therapeutic nanoliposomes for the treatment
of tumors via intravenous injection [74, 94, 95]. The
comparative dosimetric evaluation of nanotargeted 188Re-
(DXR)-liposome derived from the biodistribution indicated
that the delivery radiation doses were safe and feasible for
further clinical translation research from bench to bedside
[90]. The results for major organs doses for the 188Re-
(DXR)-liposome revealed that similar doses were received
by spleen and liver, but a lower dose was given to kidney,
compared with 111In-DTPA-octreotide therapy. Lower
doses were also received by total body and liver, compared
with 111In-DTPA-human epidermal growth factor (hEGF)
radiotherapeutics (0.19 and 0.76 mGy/MBq, respectively).
The absorbed doses for spleen, liver, kidney, and red marrow
in these studies are much lower than those from 90Y-
1,4,7,10-tetraazacyclododecane-N, N
 ,N
  ,N
   -tetraacetic
acid tyrosine octreotide (DOTATOC) therapy [90]. Table 4
lists the selected passively nanotargeted nuclear imaging and
radiotherapeutic applications. The tumor growth inhibition
and therapeutic eﬃcacy studies of passively nanotargeted
radionuclidesof 111In-(VNB)-liposomeonHT-29/luctumor
bearing in SCID mice animal model (Figure 2(b))[ 71], and
188Re-(DXR)-liposome on CT-26 solid tumor on BALB/c
mice animal model were illustrated (Figure 2(d))[ 71, 90].
The synergistic therapeutic eﬃcacy was also demonstrated
in the co-delivery of nanotargeted radiochemo-therapeutics
of 188Re-DXR-liposome [73].
4.ActiveNanotargetingDeliveryof
Radionuclides for Tumor Nuclear Imaging
and Radiotherapy
Typically, nanotargeted radionuclides have a three-
component architecture for active targeting therapeutics,
such as pegylated nanoliposome surface bioconjugated
with bioactive antibody or peptide, and encapsulated or
bioconjugated with therapeutic radionuclide payloads
for tumor-targeted nuclear imaging or radiotherapeutics
[20, 21]. In addition, tumor-speciﬁc receptor targeting of
nanocarriers could provide for high-antitumor therapeutic
activity and imaging eﬃcacy with low adverse side eﬀects
on healthy organs for practically any type of anticancer/
imaging drug delivery systems [22, 23, 41, 42]. The selected
research and applications of actively nanotargeted tumor
nuclear imaging and radiotherapeutics are summarized in
Table 5.
4.1. Active Nanotargeting Delivery of Radionuclides for Tumor
Nuclear Imaging. The ability to modify the surface of
nanocarriers permits the improvement in the pharma-
cokinetics, bioavailability, toxicity, and customization of
nanocarrier formulations for particular actively nanotar-
geted tumor imaging [96]. Enhanced tumor accumula-
tion and visualization by γ-scintigraphy with 111In-labeled
nucleosome-speciﬁc monoclonal antibody 2C5 bioconju-
gated immunoliposome has been studied, and the results
indicated better and faster imaging in various tumor-
bearing mice [45–47]. Pharmaceutical lipid-based nanocar-
riers modiﬁed with mAb 2C5 could represent a new sys-
tem for tumor-speciﬁc delivery of soluble, insoluble, and
radionuclide pharmaceuticals [45]. αvβ3-Integrin-targeted
111In perﬂuorocarbon nanoparticles have been developed
and studied for the detection of rabbit Vx-2 tumor angio-
genesis. The circulatory half-life was estimated to be 5h. The
mean tumor uptake was 4-fold higher than the nontargeted
control. The speciﬁcity activity (mCi/ml) (111In/NP) of 111In
to nanoparticle (NP) may aﬀect the tumor-to-muscle ratio
in patients. The tumor-to-muscle uptake ratios for the
nanotargeted 111In/NP = 10 to 111In/NP = 1w e r e6 . 3± 0.2
to5.1 ± 0.1,respectively.Thedatasuggestthatαvβ3-targeted
111In perﬂuorocarbon nanoparticles may provide a clinically
usefultoolfordetectingangiogenesisinnascenttumors[48].
111In radiolabeled soluble functionalized multifunctional
drug delivery platforms of active targeting with rituximab
monoclonal antibody bioconjugated on single-wall carbon
nanotubes have been developed, and the selectivity of
targeting disseminated human lymphoma was evaluated
in vitro and in vivo [40]. The results of the ability to
target tumor speciﬁcally with prototype-radiolabeled or
ﬂuorescent-labeled, antibody-appended carbon nanotube
constructs are encouraging and suggest further investigation
of carbon nanotubes as a novel radionuclide delivery plat-
form [40].
The development of a dual-function PET/near-infrared
ﬂuorescence (NIRF) molecular probe for the accurate assess-
ment of pharmacokinetics and tumor-targeting eﬃcacy of
U87MG human glioblastoma tumor-bearing mice has been
reported [37]. The amine-functionalized surface of quan-
tum dot (QD) bioconjugated with arginine-glycine-aspartic
acid (RGD) peptides and 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) for 64Cu radiolabeled
64Cu-DOTA-QD-RGD nanoconstructs with 90 RGD per
QD to target angiogenesis for application in integrin-
αvβ3 PET/NIRF imaging was also illustrated [37]. This
dual-function nuclear/optical in vivo molecular probe
revealed a quantitative targeting ability in deep tumor
lesions [37]. Dual modality optical and PET imaging of
vascular endothelial growth factor receptor (VEGFR) on8 Journal of Biomedicine and Biotechnology
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Figure 2: (a) Gamma scintigraphy of BALB/c mice bearing CT-26 tumor animal model at 24hr and 48hr after intravenous injection of
passivelynanotargetedradionuclidesof 111In-DTPA-liposome(reprintedwithpermissionfromreference[70]).(b)Tumorgrowthinhibition
with passively nanotargeted radionuclides of 111In-(VNB)-liposome on HT-29/luc tumor bearing in SCID mice animal model (reprinted
with permission from reference [71]). (c) MicroSPECT/CT images of passively nanotargeted radionuclides of 188Re-liposome and 188Re-
DXR-liposome targeting CT-26 bearing in BALB/c mice animal model at 1h, 4h, 24h, and compare with the control (reprinted with
permission from reference [72]). (d) Therapeutic eﬃcacy of tumor volume change and survival ratio for CT-26 tumor-bearing BALB/c
mice after intravenous administration of passively nanotargeted radionuclides of 188Re-(DXR)-liposome were illustrated. (reprinted with
permission from reference [73]).
tumor vasculature using QDs of 64Cu radiolabeled 64Cu-
DOTA-QD-VEGF was also investigated [38]. The U87MG
tumoruptakeofactivenanotargeted 64Cu-DOTA-QD-VEGF
(1.52 ± 0.6 % injected dose/gram (%ID/g), 2.81 ± 0.3
%ID/g, 3.84 ± 0.4 %ID/g, and 4.16 ± 0.5 %ID/g at 1, 4,
16, and 24h, respectively, postinjection) was one percentage
injected dose per gram (%ID/g) higher than that of passively
targeted 64Cu-DOTA-QD [38]. 18F-labeled phospholipids
quantum dot micelles for in vivo PET and optical ﬂu-
orescence imaging from cells to whole body have been
designed and studied [39]. Development of a bifunctional
nanotargeted iron oxide (IO) molecular probe for PET and
magnetic resonance imaging (MRI) of tumor integrin-αvβ3
expression was reported; this bifunctional 64Cu-DOTA-IO-
RGD nanotargeted molecular imaging approach may allow
for earlier tumor detection and may provide insight into
the molecular mechanisms of cancer [32, 33]. The synthesis
and in vivo characterization of an 18F-labeled trimodal
(MRI/PET-CT/optical) iron oxide(IO) for tumor imaging,
the facile conjugation chemistry, provides a simple platform
for rapid and eﬃcient IO labeling [34]. Tumor targeting
angiogenesis and comparison of 99mTc-labeled peptide and
99mTc-labeled polymer-peptide nanocarrier conjugates were
investigated [35]. Speciﬁc targeting of the αvβ3 integrin
and nonspeciﬁc vascular permeability are both signiﬁcant,
but active speciﬁc targeting is more important than EPR
of the carrier molecule. Nonspeciﬁc vascular permeability
appears to be a major factor in reducing tumor-to-normal
tissue localization ratio for the peptide molecules [35].
Biodegradable 76Br-labeled dendritic bioconjugated RGD
bifunctional nanoprobes for the noninvasive PET imaging of
angiogenesiswasreported[36].Figure 3demonstratedthein
vivoactivelynanotargetedradionuclidesof 64Cu-DOTA-QD-
RGD for dual-function PET and near-infrared ﬂuorescence
(NIR) imaging of a U87MG tumor vasculature mice animal
model [37].
4.2. Active Nanotargeting Delivery of Radionuclides for Tumor
Radiotherapeutics. Signiﬁcant radiation-induced antisense-
mediated cytotoxicity of tumor cells in vitro was achieved
using an auger electron-emitting antisense antiR1α messen-
ger RNA antisense morpholino (MORF) oligomer admin-
istered as a member of a three-component streptavidin-
delivery nanoparticle (111In-MORF/tat/trastuzumab) [50].
Targeted angiogenesis αvβ3 and VEGFR2 with three-
component actively nanotargeted radionuclides of 90Y-
liposome-IA (integrin antagonist) and 90Y-liposome-anti-
Flk-1 (mAb) have been reported in murine melanoma
K1735-M2 and colon CT26 animal models [49]. The results
demonstrated that 90Y-liposome-anti-Flk-1 (mAb) was sig-
niﬁcantly more eﬃcacious than conventional radioim-
munotherapy in the mouse melanoma model [49].
Enhanced targeting, loading and retention of 225Ac,
and three α-particle-emitting daughters of 225Ac by actively
nanotargeted immunoliposomes have also been illustrated
[82–84]. The eﬃcacy and successful treatment of tumors
by BNCT depend on the selective delivery of relatively high
amounts of 10B to tumors. Application of active folate-
receptor targeted PAMAM-dendrimers and active cetuximab
immunoliposome-entrapped 10B delivery systems has been10 Journal of Biomedicine and Biotechnology
Table 4: Selected passively nanotargeted tumor nuclear imaging and radiotherapeutic applications.
Nanoparticles Radionuclides Imaging or Radiotherapeutics Applications Reference
Liposomes 99mTc, 111In, 67Ga, 99mTc Gamma imaging
Multitude diagnostics of tumor,
infection, Inﬂammation, and
lymphoscintigraphy
[28, 29, 60–62]
Liposomes 111In Gamma/SPECT imaging
Clinical biodistribution, PK and imaging
studies of breast, head and neck, glioma
and lung cancer patients
[53, 62]
Liposomes 18F PET imaging Liposomal tracking in vivo with
18F-limposome-PET imaging
[66–68]
Liposomes 111In, 177Lu Gamma/SPECT imaging Gamma imaging of tumor targeting for
C26 and HT29/luc animal models
[70, 71]
Liposomes 64Cu PET imaging
Passive targeted delivery and imaging
with bioconjugated 64Cu-BAT-
PEG-liposome
[69]
Liposomes 131I, 90Y, 188Re, 67Cu Radiotherapeutics
An analytical dosimetry study for the use
of radionuclide-liposome conjugates in
internal radiotherapy
[74]
Liposomes 186Re Radiotherapeutics
Intraoperative 186Re-liposome
radionuclide therapy in a head and neck
squanous cell carcinoma xenograft
positive surgical margin model
[78]
Liposomes 111In, 188Re Radiotherapeutics
Imaging, biodistribution,
pharmacokinetics, and therapeutic
eﬃcacy studies of 111In/188Re-liposome
on C26 and HT-29 tumor-bearing animal
models
[70, 72, 80, 81]
Liposomess 225Ac Radiotherapeutics
Targeted α-particles emitters of
225Ac-generators encapsulated in
liposomes as therapeutic agents for
micrometastases cancer
[82–84]
Liposomes 10B Radiotherapeutics
10B-liposomes nanotargeted therapeutics
for boron neutron capture therapy
(BNCT)
[85, 86]
Liposomes 111In, 188Re Radiochemo-therapeutics
Imaging, biodistribution,
pharmacokinetics, therapeutic eﬃcacy,
and dosimetry studies of
111In/188Re-VNB/DXR-liposome on C26
and HT-29 tumor/ascites-bearing animal
models
[71, 73, 81, 90–93]
mAb: monoclonal antibody, CNT: carbon nanotube, QD: quantum dots, IO: iron oxide.
studied for BNCT applications in animal models [51, 52].
Major challenges that have to be addressed by drug-delivery
nanocarriers in cancer therapy are the low drug bioavail-
ability of therapeutics within cancer cells and the high
toxicities at normal organs due to the low tumor targeting
or localization. The combination of molecular targeting
of bioconjugated nanoparticles or immunoliposomes can
provide targeted cell internalization and intracellular drug
release to improve anticancer therapeutic eﬃcacy and to
reduce toxicity [97]. Active receptor nanotargeted polymers,
dendrimers,andliposomesemployedfortargetingtotumor-
speciﬁc receptors can prevent serious adverse side eﬀects
on healthy organs. In addition, the internalization and
intracellular distribution of nanocarriers in cancer cells
indicated that tumor-speciﬁc receptor active targeting of
nanocarriers could provide high antitumor therapeutic
activity and imaging eﬃcacy with low adverse side eﬀects on
normal tissues [41].
4.3. Nanoparticles for Concurrent Multimodality Nuclear
Imaging and Radiotherapeutics. Nanoparticles have advan-
tages for cancer nuclear imaging and radiotherapy. The
ultimate goal in the design and preparation of multifunc-
tional and multimodality nanoparticles in drug delivery
is the creation of combined diagnostics and therapeutics
(or theragnostics) and combined radiochemo-therapeutics
for the targeted diagnosis and treatment of cancer [44,
97]. Recent advances in the ﬁeld of nanotechnology and
nanomedicine indeed oﬀer the promise of better diagnostic
and therapeutic options. Newer generation of nanoparticles
has been designed and synthesized to target speciﬁc types
of cell and molecule via aﬃnity ligands from phage orJournal of Biomedicine and Biotechnology 11
Table 5: Selected actively nanotargeted tumor nuclear imaging and radiotherapeutic applications.
Nanoparticles Radionuclides Imaging or
Radiotherapeutics Applications Reference
Immunoliposome 111In Gamma imaging and
therapeutics
111In-liposome-2C5(mAb)
nucleosome-speciﬁc monoclonal 2C5 targeting
delivery vehicles for tumor visualization of
murine lewis lung carcinoma and human
HT-29 tumors
[45–47]
Perﬂuorocarbon
nanoparticles
111In Gamma imaging Imaging of targeted tumor angiogenesis of
αvβ3-integrin in Vx-2 rabbit tumors
[48]
Carbon nanotubes 111In Gamma or SPECT imaging
Multifunctional targeted delivery and imaging
with. functionalized and bioconjugated
111In-DOTA-CNT-Rituximab nanoconstructs
[40]
Quantum dots 64Cu Bifunctional PET/NIRF
imaging
Dual-functional targeted delivery with amine
functionalized 64Cu-DOTA-QD-RGD for
tumor angiogenesis PET/NIRF imaging
[37]
Quantum dots 64Cu Bifunctional PET/NIRF
imaging
Dual-functional targeted delivery with amine
functionalized 64Cu-DOTA-QD-VEGF for
tumor angiogenesis PET/NIRF imaging
[38]
Quantum dots 18F Bifunctional PET/optical
imaging
18F labeled phospholipids quantum dot
micelles for in vivo multimodal imaging
[39]
Iron oxide 64Cu Bifunctional PET/MRI
imaging
PET/MRI dual-modality tumor angiogenesis
imaging with 64Cu-DOTA-IO-RGD
nanoconstructs
[32, 33]
Iron oxide 18F
Trimodel
MRI/PET-CT/optical
imaging
18F labeled iron oxide for in vivo PET-CT
imaging
[34]
Polymer 99mTc Scintigraphic images of
tumor targeting
Targeting tumor angiogenesis: comparison of
99mTc -peptide and 99mTc -polymer-peptide
conjugates
[35]
Dendrimers 76Br RGD directed-demdrimers
PET imaging
76Br labeled RGD-directed-dendritic
nanoprobes for PET imaging of angiogenesis
[36]
Streptavidin 111In Radiotherapeutics
111In labeled 3-component streptavidin
(111In-MORF/tat/trastuzmab) nanoparticles
for auger electron induced antisense-mediated
cytoxicity of tumor cells
[50]
Immunoliposomes 90Y Radiotherapeutics
Targeted antiangiogenesis of αvβ3-integrin or
VEGFR2 anti-FLK-1 therapy with
nanotargeted therapeutics of
90Y-DTPA-liposome-IA(integrin antagonist) or
90Y-DTPA-liposome-mAb
[49]
Immunoliposomes 225Ac Radiotherapeutics
Targeted α-particles emitters of
225Ac-generators encapsulated in liposomes as
therapeutic agents for micrometastases cancer
[82–84]
Immunoiposomes and
Folate-dendrimers
10B Radiotherapeutics
10B-immunoliposomes-anti-EGFR and
10B-PAMAM dendrimers-anti-folate
nanotargeted therapeutics for boron neutron
capture therapy (BNCT)
[51, 52]
small molecules, or involving antibodies or peptides for
nanotargeted radionuclide or drug concurrent delivery.
Synergistically integrated nanoparticles with multifunc-
tional and multimodality novel core platform for cancer
nuclear imaging and radiotherapeutics have been developed
[98]. Important multifunctions include imaging (single
or multimodality), therapy (single drug or combination
of two or more drugs), and targeting (one or more
ligands) with multivalent. For example, binary nanopar-
ticles with two functions could be developed for simul-
taneous molecular imaging and targeted therapy, ternary
nanoparticles with three functions could be designed for
simultaneous imaging, therapy and targeting, targeted dual-
modality imaging, or targeted dual-modality therapy. Some
typical and potential nanoparticles for nuclear imaging
and therapeutics are illustrated as follows: (i) radionuclide12 Journal of Biomedicine and Biotechnology
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Figure 3: In vivo actively nanotargeted radionuclides of 64Cu-DOTA-QD-RGD for dual-function PET and near-infrared ﬂuorescence (NIR)
imaging of U87MG tumor vasculature mice animal model. (a) PET images of 64Cu-labeled nanoparticles of DOTA-QD or DOTA-QD-
RGD. Arrow heads indicate tumors. (b) Liver uptake of 64Cu-labeled nanoparticles of DOTA-QD or DOTA-QD-RGD. (c) U87MG tumor
uptake of 64Cu-labeled nanoparticles of DOTA-QD or DOTA-QD-RGD. (d) Two-dimensional image of the 2 mice shown in (a) at 5hr after
injection (reprinted with permission from reference [37]). DOTA: 1,4,7,10-tetraazacyclodocecane- N, N
 ,N
  ,N
   - tetraacetic acid chelators
for radionuclides labeling. QD: Quantum dots conjugated with NIR probe. RGD: Arginine-glycine-aspartic acid peptide for targeting tumor
angiogenesis integrin αvβ3.
(e.g., 111In/188Re/64Cu)-labeled passively nanotargeted mul-
timodel nanoliposomes [90–92] or actively nanotargeted
multifunctional and multimodal immunoliposomes [45–
47, 99–101], (ii) radionuclide (e.g., 18F/64Cu)-labeled iron
oxide magnetic nanoparticles for multimodal and multi-
valent MRI-PET-optical imaging agents and therapeutics
[32–34] (iii) radionuclide (e.g.,18F/64Cu)-labeled QDs for
multifunctional and multimodal imaging and therapeutics
[37–39, 59, 102] and (iv) silica nanoparticles as a platform
for multimodality imaging agents and therapeutics [103,
104]. The simultaneous attainment of preferential localiza-
tion and avoidance of the sequential biological barriers,Journal of Biomedicine and Biotechnology 13
such as RES system uptake, has been studied with a
multifunctional multistage delivery system of mesoporous
silicon particles for imaging and therapeutic applications
[105]. Development of multidrug resistance (MDR) is one
of the most challenging aspects of cancer chemotherapy.
Bimodality codelivery chemotherapeutics in nanoemulsion
formulations has shown to be very eﬀective in enhancing the
cytotoxicity in wild-type and resistant tumor cells [106].
5.Nano-/Radiotoxicology
Although nanocarriers have provided some new break-
throughs for cancer diagnosis and therapy, the potential
adverse human health eﬀects resulting from exposure to
nanoparticles should also be a concern [22, 107, 108].
Research shows that nanoparticles can stimulate and/or
suppress the immune response, and that their compatibility
with the immune system is largely determined by their
surface chemistry. Modifying these factors can signiﬁcantly
reduce the immunotoxicity of nanoparticles and make them
useful platforms for drug delivery [43]. The biodistribution
and movements of nanoparticles through tissues and the
phagocytosis and endocytosis of nanoparticles would all
likely aﬀect the potential toxicity of nanoparticles. The prac-
ticalstrategiesforidentifyingandcontrollinginterferencesin
common evaluation methods and the implications for regu-
lation of nanoparticle immunotoxicity have been discussed
and suggested [109]; the standardization of nanoparticle-
tuned methods through international “round robin” inter-
laboratory testing was proposed [109]. Toxicity of nanocar-
rier systems involves physiological, physicochemical, and
molecular considerations. Nanocarrier systems may induce
cytotoxicity and/or genotoxicity [110]. To minimize the risks
posed by nanomaterials, there are two basic avenues. One
is to develop new highly biocompatible nanomaterials with
low toxicity. The other is surface modiﬁcation of nanopar-
ticles with biocompatible chemicals. Many great eﬀorts are
being made to develop nanoparticles satisfactory for clinical
applications, but nanoregulation is still undergoing major
changes to encompass environmental, health, and safety
issues [43, 107, 108, 110]. QDs larger than the renal ﬁltration
threshold quickly accumulate in the RES system following
intravenous administration. Great concern has been raised
over the use of quantum dots in living cells and animals due
to their chemical composition of toxic heavy-metal atoms
(e.g., Cd, Hg, Pb, As) [59].
Radiolabeled pegylated liposomes have demonstrated
eﬀective targeting of solid tumors in patients by nuclear
imaging [53]. There were no important adverse reac-
tions attributable to the liposome infusion, and repeated
hematological and biochemical proﬁles performed at day
10 showed no signiﬁcant changes [53]. Absorbed dose
calculations provide a scientiﬁc basis for evaluating the
biological eﬀects associated with administrated radiophar-
maceuticals. In cancer therapy, radiation dosimetry supports
treatment planning, dose-response analyses, predications
of therapy eﬀectiveness and safety [111]. An analytical
dosimetry study for the use of radionuclide (67Cu, 131I,
188Re, and 90Y)-liposome in internal radiotherapy has been
reported [74]. Unlike the case with radioimmunother-
apy, the dose-limiting organ is likely to be the liver,
and strategies intended to reduce RES accumulation are
needed to further improve such a tumor-targeting approach
[74]. We have studied the radiation dosimetric analysis of
passively nanotargeted radiotherapeutics of 188Re-liposome
and radiochemo-therapeutics of 188Re-DXR-liposome with
OLINDA/EXM software for system-targeted radionuclide
therapy. The results showed that the red marrow was to be
the critical organ in determining the maximally tolerated
absorbed doses, and it was promising and beneﬁcial to
carry out further preclinical and clinical investigations [90].
Comparisons with the radiation-absorbed dose estimates
for 111In- and 90Y-ibritumomab tiuxetan, and the radiation
absorbed per unit administered activity (mGy/MBq) for
nanotargeted 188Re-(DXR)-liposomeweremuchlowerinthe
major organs [90, 111].
6. Conclusions andFutureProspective
Recent advances in the ﬁeld of nanotechnology applications
in biomedicine oﬀer the promise of better diagnostic and
therapeutic options. Medicine and synthetic scientists are
making strides in developing nanoconstructs that can be
used as core platforms for attaching diﬀerent function-
alities by surface conjugating or after-loading of various
nanoparticles for the purposes of cancer molecular imaging
and targeted drug delivery. As compared with conventional
targeted radionuclide therapy or radioimmunotherapy, the
use of nanocarriers can allow for speciﬁc multivalent
attachment of targeted molecules of antibodies, peptides,
or ligands to the surface of nanocarriers. Nanotargeted
radionuclide therapy can deliver a high payload of radionu-
clides, chemotherapeutics, and/or imaging agents to achieve
multifunctional and multimodality targeting to tumor cells.
The new nanocarrier drug delivery system platform can
enhance the eﬃcacy and safety of targeted therapy. Future
clinical trial studies are required to translate those advanced
technologies to the health care of cancer patients. The
optimization of the nanoparticle compositions and struc-
ture, the simultaneous attainment of preferential targeting
location, reducing immunotoxic eﬀect, and the avoidance
of sequential biological barriers of the nanoparticles are the
major challenges in the future research and development of
passively and actively nanotargeted drug delivery systems.
Several passively nanotargeted radiolabeled nanocarriers
have been successfully employed to image and treat tumor
models both preclinically and clinically. Future studies
should be designed to optimize these novel approaches and
to combine targeted delivery, potent radionuclides, imaging
agents, chemotherapeutics and/or radiosensitizing agents.
We have demonstrated that a co-delivery of radiochemo-
therapeuticsandsimultaneousmultifunctionalimagingisan
advantageous characteristic of nanotargeted radionuclides
for cancer imaging and therapy. A good multidisciplines
and multi-institutes collaboration between the academia,
research institutes, and industry combing with an integrated14 Journal of Biomedicine and Biotechnology
“bench-to-clinic” translational approach would accelerate
the progress in research of nanotargeted radionuclides
toward clinical applications for the healthcare of cancer
patients.
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